Table 2.
Incidence of acne events by severity, sex, and age (16-week placebo-controlled period)
| UPA 15 mg + TCS, N = 91 | UPA 30 mg + TCS, N = 91 | Placebo + TCS, N = 90 | |
|---|---|---|---|
| Parameter, n (%) | |||
| Patients with acne events | 12 (13.2) | 18 (19.8) | 5 (5.6) |
| Severity | |||
| Mild | 7 (7.7) | 11 (12.1) | 4 (4.4) |
| Moderate | 5 (5.5) | 7 (7.7) | 1 (1.1) |
| Severe | 0 | 0 | 0 |
| Acne leading to discontinuation of study drug | 0 | 0 | 0 |
| Characteristic, n/N (%) | |||
| Sex | |||
| Male | 9/68 (13.2) | 11/69 (15.9) | 4/74 (5.4) |
| Mild | 5/9 (55.6) | 6/11 (54.5) | 4/4 (100) |
| Moderate | 4/9 (44.4) | 5/11 (45.5) | 0 |
| Female | 3/23 (13.0) | 7/22 (31.8) | 1/16 (6.3) |
| Mild | 2/3 (66.7) | 5/7 (71.4) | 0 |
| Moderate | 1/3 (33.3) | 2/7 (28.6) | 1/1 (100) |
| Age | |||
| < 18 years | 1/8 (12.5) | 2/8 (25.0) | 1/9 (11.1) |
| 18 to < 30 years | 7/23 (30.4) | 7/30 (23.3) | 2/21 (9.5) |
| 30 to < 40 years | 3/22 (13.6) | 4/17 (23.5) | 0/23 (0) |
| 40 to < 65 years | 1/37 (2.7) | 5/35 (14.3) | 2/37 (5.4) |
| ≥ 65 years | 0/1 (0) | 0/1 (0) | 0/0 (0) |
TCS topical corticosteroids, UPA upadacitinib